Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Stage III or IV Malignant Melanoma”

150 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 150 results

Early research (Phase 1)Study completedNCT00217542
What this trial is testing

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Who this might be right for
Recurrent MelanomaRecurrent Renal Cell CancerStage III Melanoma+2 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Study completedNCT00110994
What this trial is testing

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
CancerMelanoma
Bayer 101
Large-scale testing (Phase 3)Study completedNCT01006980
What this trial is testing

Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 675
Testing effectiveness (Phase 2)Study completedNCT00602576
What this trial is testing

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Who this might be right for
Melanoma (Skin)
Abramson Cancer Center at Penn Medicine 169
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)UnknownNCT01168050
What this trial is testing

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Who this might be right for
Malignant Skin Melanoma T0Stage III MelanomaStage IV Melanoma+1 more
Assistance Publique - Hôpitaux de Paris 25
Early research (Phase 1)Study completedNCT01489059
What this trial is testing

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 42
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT00261365
What this trial is testing

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Who this might be right for
Unresectable Stage III or IV Malignant Melanoma
Bristol-Myers Squibb 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT01676649
What this trial is testing

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

Who this might be right for
Untreated Stage III Melanoma or Stage IV Melanoma
Jewish General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00612664
What this trial is testing

Phase II, 2nd Line Melanoma - RAND Monotherapy

Who this might be right for
Melanoma
Bristol-Myers Squibb 158
Large-scale testing (Phase 3)Study completedNCT00094653
What this trial is testing

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Who this might be right for
MelanomaMetastases
Bristol-Myers Squibb 1,783
Testing effectiveness (Phase 2)Active Not RecruitingNCT02910700
What this trial is testing

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Who this might be right for
Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaStage III Cutaneous Melanoma AJCC v7+5 more
M.D. Anderson Cancer Center 52
Early research (Phase 1)Ended earlyNCT03565406
What this trial is testing

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 11
Early research (Phase 1)Study completedNCT00349206
What this trial is testing

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Who this might be right for
MelanomaRecurrent MelanomaStage III Melanoma+1 more
National Cancer Institute (NCI) 69
Testing effectiveness (Phase 2)Ended earlyNCT01474551
What this trial is testing

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 2
Testing effectiveness (Phase 2)Study completedNCT02872259
What this trial is testing

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Who this might be right for
Melanoma
Haukeland University Hospital 74
Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Load More Results